Skip to content
value.today
CytoDyn Inc. logo

CytoDyn Inc.

Total raised
$11 M
2 rounds on record
Latest round
$8 M
Oct 2012
First round on record
Dec 2011
Today
Went public
See the company page

CytoDyn Inc. is listed today as CytoDyn Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 14 other private sales on record. Open the number of investors for the round's details.

Funding rounds of CytoDyn Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2026$19 MPrivate placement after listing$10 to $50 million

CytoDyn Inc.: Private sale, Jan 2026

Investors in this round

194 investors had bought by the notice of May 11, 2026: 194 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $19 M offered
Smallest investment taken
$15,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,275,050
Finders' fees
none
Paid to its own people
$1,616,900 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jacob P. Lalezari · Executive Officer
  • Robert E. Hoffman · Executive Officer
  • Tyler E. Blok · Executive Officer
  • Karen J. Brunke, Ph.D. · Director
  • Lishomwa C. Ndhlovu, M.D., Ph.D. · Director
  • Ryan M. Dunlap · Director
  • Stephen M. Simes · Director
  • Tanya D. Urbach · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company (CRD 5670) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Excludes warrants to purchase Common Stock.”

Signed by Tyler Blok, Chief Legal Officer. Source: SEC Form D, newest notice filed May 11, 2026. Read the notice at the SEC.

equity, optionsSEC
Apr 2022$22 MPrivate placement after listing$10 to $50 million

CytoDyn Inc.: Private sale, Apr 2022

Investors in this round

166 investors had bought by the notice of Sep 19, 2022: 166 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
$5,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Common Stock; Warrants to Purchase Common Stock; Common Stock issued upon exercise of Warrants
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,830,299
Finders' fees
none
Paid to its own people
$600,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Antonio Durkee Migliarese · Executive Officer
  • Arvin Cyrus Arman · Executive Officer
  • Nitya G. Ray · Executive Officer
  • Scott A. Kelly · Executive Officer, Director
  • Karen J. Brunke · Director
  • Lishomwa C. Ndhlovu · Director
  • Ryan G. Dunlap · Director
  • Tanya Durkee Urbach · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company (CRD 5670) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Excludes warrants to purchase Common Stock.”

Signed by Antonio Migliarese, CFO & Interim President. Source: SEC Form D and 2 amendments, newest notice filed Sep 19, 2022. Read the notice at the SEC.

equity, optionsSEC
Nov 2021$11 MPrivate placement after listing$10 to $50 million

CytoDyn Inc.: Private sale, Nov 2021

Investors in this round

118 investors had bought by the notice of Dec 3, 2021: 118 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $54 M offered; $42 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$6,481,244
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Antonio Durkee Migliarese · Executive Officer
  • Christopher G. Recknor · Executive Officer
  • Nader Z. Pourhassan · Executive Officer, Director
  • Nitya G. Ray · Executive Officer
  • Scott A. Kelly · Executive Officer, Director
  • Harish Z. Seethamraju · Director
  • Jordan G. Naydenov · Director
  • Lishomwa C. Ndhlovu · Director
  • Tanya Durkee Urbach · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company (CRD 5670) · New York, New YorkSold in AL, AZ, CA, CO, CT, FL, GA, IL, MD, MI, MN, MS, MT, NC, NJ, NV, NY, OK, OR, PA, SC, TN, TX, UT, VA, WA

Remarks in the notice

  • On fees: “Assumes maximum commissions earned. Excludes warrants to purchase Common Stock.”

Signed by Antonio Migliarese, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 3, 2021. Read the notice at the SEC.

equity, optionsSEC
Aug 2021$3 MPrivate placement after listing$2 to $10 million

CytoDyn Inc.: Private sale, Aug 2021

Investors in this round

6 investors had bought by the notice of Sep 16, 2021: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $25 M offered; $22 M still to sell
Smallest investment taken
$250,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Antonio G. Migliarese, C.P.A. · Executive Officer
  • Christopher G. Recknor, M.D. · Executive Officer
  • Nader Z. Pourhassan, Ph.D. · Executive Officer, Director
  • Nitya G. Ray, Ph.D. · Executive Officer
  • Scott A Kelly, M.D. · Executive Officer, Director
  • Alan P. Timmins · Director
  • Gordon A. Gardiner · Director
  • Jordan G. Naydenov · Director
  • Samir R. Patel, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Antonio Migliarese, Cfo. Source: SEC Form D, newest notice filed Sep 16, 2021. Read the notice at the SEC.

equitySEC
Nov 2020$1 MPrivate placement after listingUnder $2 million

CytoDyn Inc.: Private sale, Nov 2020

Investors in this round

1 investor had bought by the notice of Dec 16, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$1,000,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arian G. Colachis · Executive Officer
  • Mahboob G. Rahman, M.D., Ph.D. · Executive Officer
  • Michael D. Mulholland · Executive Officer
  • Nader Z Pourhassan, Ph.D · Executive Officer, Director
  • Nitya G. Ray, Ph.D. · Executive Officer
  • Scott Kelly, M.D. · Executive Officer, Director
  • Alan P. Timmins · Director
  • Jordan G. Naydenov · Director
  • Samir R. Patel, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Arian Colachis, VP, Secretary and General Counsel. Source: SEC Form D, newest notice filed Dec 16, 2020. Read the notice at the SEC.

equitySEC
Jan 2020$8 MPrivate placement after listing$2 to $10 million

CytoDyn Inc.: Private sale, Jan 2020

Investors in this round

3 investors had bought by the notice of Apr 7, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $11 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arian F Colachis · Executive Officer
  • Craig Z Eastwood · Executive Officer
  • Nader Z Pourhassan · Executive Officer, Director
  • Alan P Timmins · Director
  • David F Welch · Director
  • Jordan G Naydenov · Director
  • Scott A Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Craig Eastwood, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Apr 7, 2020. Read the notice at the SEC.

equity, optionsSEC
Mar 2019$8 MPrivate placement after listing$2 to $10 million

CytoDyn Inc.: Private sale, Mar 2019

Investors in this round

61 investors had bought by the notice of Nov 12, 2019: 61 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $20 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Convertible Preferred Stock with Warrants
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,800,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael D. Mulholland · Executive Officer
  • Nader Z. Pourhassan · Executive Officer, Director
  • David F. Welch · Director
  • Jordan G. Naydenov · Director
  • Michael A. Klump · Director
  • Scott A. Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, LLC (CRD 5670) · Chicago, IllinoisSold in all US states

Remarks in the notice

  • On fees: “Assumes maximum fees earned.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Michael D. Mulholland, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 12, 2019. Read the notice at the SEC.

equity, optionsSEC
Aug 2018$13 MPrivate placement after listing$10 to $50 million

CytoDyn Inc.: Private sale, Aug 2018

Investors in this round

119 investors had bought by the notice of Sep 10, 2018: 119 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $25 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael D. Mulholland · Executive Officer
  • Nader Z. Pourhassan · Executive Officer, Director
  • Anthony D. Caracciolo · Director
  • Carl C. Dockery · Director
  • Gregory A. Gould · Director
  • Jordan G. Naydenov · Director
  • Michael A. Klump · Director
  • Scott A. Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, LLC (CRD 5670) · Chicago, IllinoisSold in all US states

Remarks in the notice

  • On fees: “Assumes maximum commissions earned. Excludes value of warrants to purchase up to 5,000,000 shares of common stock.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Michael D. Mulholland, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 10, 2018. Read the notice at the SEC.

equity, optionsSEC
Nov 2017$18 MPrivate placement after listing$10 to $50 million

CytoDyn Inc.: Private sale, Nov 2017

Investors in this round

200 investors had bought by the notice of Feb 28, 2018: 200 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,714,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anthony D. Caracciolo · Executive Officer, Director
  • Michael D. Mulholland · Executive Officer
  • Nader Z. Pourhassan · Executive Officer, Director
  • Alan Bruce Montgomery · Director
  • Carl C. Dockery · Director
  • Denis R. Burger · Director
  • Gregory A. Gould · Director
  • Jordan G. Naydenov · Director
  • Scott A. Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, LLC (CRD 5670) · Chicago, IllinoisSold in all US states

Remarks in the notice

  • On fees: “Excludes value of warrants to purchase up to 2,813,490 shares of common stock.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Michael D. Mulholland, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 28, 2018. Read the notice at the SEC.

equity, optionsSEC
May 2017$1 MPrivate placement after listingUnder $2 million

CytoDyn Inc.: Private sale, May 2017

Investors in this round

2 investors had bought by the notice of Jun 14, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $15 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,266,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anthony D. Caracciolo · Executive Officer, Director
  • Michael D. Mulholland · Executive Officer
  • Nadar Z. Pourhassan · Executive Officer, Director
  • Alan Bruce Montgomery · Director
  • Carl C. Dockery · Director
  • Denis R. Burger · Director
  • Gregory A. Gould · Director
  • Jordan G. Naydenov · Director
  • Scott A. Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, LLC (CRD 5670) · Chicago, IllinoisSold in all US states

Remarks in the notice

  • On fees: “Assumes maximum commissions are earned. Excludes value of warrants to purchase shares of common stock.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Michael D. Mulholland, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 14, 2017. Read the notice at the SEC.

debt, optionsSEC
Apr 2016$4 MPrivate placement after listing$2 to $10 million

CytoDyn Inc.: Private sale, Apr 2016

Investors in this round

41 investors had bought by the notice of May 11, 2016: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $10 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$196,665
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael D. Mulholland · Executive Officer
  • Nadar Z. Pourhassan · Executive Officer, Director
  • Alan Bruce Montgomery · Director
  • Anthony D. Caracciolo · Director
  • Carl C. Dockery · Director
  • Denis R. Burger · Director
  • Gregory A. Gould · Director
  • Jordan G. Naydenov · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, LLC (CRD 5670) · Chicago, IllinoisSold in all US states

Remarks in the notice

  • On fees: “Placement Agent also received warrants to purchase up to 132,050 common shares.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Michael D. Mulholland, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed May 11, 2016. Read the notice at the SEC.

equity, optionsSEC
Sep 2015$3 MPrivate placement after listing$2 to $10 million

CytoDyn Inc.: Private sale, Sep 2015

Investors in this round

67 investors had bought by the notice of Oct 5, 2015: 67 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: amended warrants
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$107,752
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael D. Mulholland · Executive Officer
  • Nadar Z. Pourhassan · Executive Officer, Director
  • Alan Bruce Montgomery · Director
  • Anthony D. Caracciolo · Director
  • Carl C. Dockery · Director
  • Denis R. Burger · Director
  • Gregory A. Gould · Director
  • Jordan G. Naydenov · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, LLC (CRD 5670) · Chicago, IllinoisSold in all US states

Remarks in the notice

  • On the amounts: “Conversion of indebtedness in exchange for common stock and amended warrants.”

Signed by Michael D. Mulholland, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Oct 5, 2015. Read the notice at the SEC.

equitySEC
Jun 2015$33 MPrivate placement after listing$10 to $50 million

CytoDyn Inc.: Private sale, Jun 2015

Investors in this round

261 investors had bought by the notice of Feb 23, 2016: 261 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$33 M of $33 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,598,460
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael D. Mulholland · Executive Officer
  • Nadar Z. Pourhassan · Executive Officer, Director
  • Alan Bruce Montgomery · Director
  • Anthony D. Caracciolo · Director
  • Carl C. Dockery · Director
  • Denis R. Burger · Director
  • Gregory A. Gould · Director
  • Jordan G. Naydenov · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, LLC (CRD 5670) · Chicago, IllinoisSold in all US states

Remarks in the notice

  • On fees: “Placement agent also received warrants to purchase up to 4,797,932 common shares.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Michael D. Mulholland, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D and 1 amendment, newest notice filed Feb 23, 2016. Read the notice at the SEC.

equity, optionsSEC
Sep 2013$15 MPrivate placement after listing$10 to $50 million

CytoDyn Inc.: Private sale, Sep 2013

Investors in this round

170 investors had bought by the notice of Oct 29, 2013: 170 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$1,816,400
Finders' fees
none
Paid to its own people
$650,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Colorado

People named in the notice

  • Michael Mulholland · Executive Officer
  • Nadar Pourhassan · Executive Officer, Director
  • Alan Bruce Montgomery · Director
  • Anthony Caracciolo · Director
  • Gregory Gould · Director
  • Jordan Naydenov · Director
  • Michael Nobel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, Inc. (CRD 5670) · Portland, OregonSold in AZ, CA, CO, CT, FL, GA, IA, IL, IN, LA, MA, MD, MI, MN, MS, NC, ND, NH, NJ, NM, NV, NY, OH, OK, OR, PA, SD, TX, UT, VA, WA, WI

Remarks in the notice

  • On fees: “Compensation to the placement agent also includes warrants to purchase appx 4,940,125 common shares. In addition, a 6% cash fee applies to exercises of investor warrants.”
  • On the use of proceeds: “Represents compensation paid or payable to directors and executive officers in the ordinary course of business.”

Signed by Michael D. Mulholland, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D and 1 amendment, newest notice filed Oct 29, 2013. Read the notice at the SEC.

equity, optionsSEC
Oct 2012$8 MNo. 2$2 to $10 million

CytoDyn Inc.: Raise no. 2, Oct 2012

Investors in this round

34 investors had bought by the notice of Aug 5, 2013: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $10 M offered; $2 M still to sell
Smallest investment taken
$25,000
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$120,000
Finders' fees
none
Paid to its own people
$750,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Colorado

People named in the notice

  • Michael Mulholland · Executive Officer
  • Nader Pourhassan · Executive Officer, Director
  • Anthony Caracciolo · Director
  • Gregory Gould · Director
  • Jordan Naydenov · Director
  • Michael Nobel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, Inc. (CRD 5670) · Portland, OregonSold in CA, CO, FL, MI, MN, NJ, NY, OR, SD, WA, WI

Remarks in the notice

  • On the use of proceeds: “Represents compensation paid or payable to directors and executive officers in the ordinary course of business.”

Signed by Michael D. Mulholland, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D and 2 amendments, newest notice filed Aug 5, 2013. Read the notice at the SEC.

equity, debt, optionsSEC
Dec 2011$3 MNo. 1$2 to $10 million

CytoDyn Inc.: Raise no. 1, Dec 2011

Investors in this round

86 investors had bought by the notice of Jan 17, 2012: 86 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$1,500
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Colorado

People named in the notice

  • Andrew T. Libby, Jr. · Executive Officer
  • Kenneth J. Van Ness · Executive Officer, Director
  • Anthony D. Caracciolo · Director
  • George F. Dembow · Director
  • George J. Gould, CPA · Director
  • Jordan F. Naydenov · Director
  • Ronald J. Tropp, Esq. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The offering has terminated and the remaining amount will not be sold.”

Signed by Kenneth J. Van Ness, President, Chief Executive Officer, and Director. Source: SEC Form D, newest notice filed Jan 17, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • CytoDyn Inc. chose not to state its revenue in its newest notice of a funding round (May 2026).

    SEC Form D · May 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2026

That is all the official record says: CytoDyn Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of CytoDyn Inc. are on record.

Investors#

No investor of CytoDyn Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 86 investors.

Largest shareholders today

Institutions holding CytoDyn Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CytoDyn Inc.
NameRoleNamed in
Jacob P. LalezariExecutive officerMay 2026
Robert E. HoffmanExecutive officerMay 2026
Tyler E. BlokExecutive officerMay 2026
Antonio Durkee MigliareseExecutive officerSep 2022
Arvin Cyrus ArmanExecutive officerSep 2022
Nitya G. RayExecutive officerSep 2022
Scott A. KellyExecutive officerSep 2022
Antonio G. MigliareseExecutive officerApr 2022
Christopher G. RecknorExecutive officerDec 2021
Nader Z. PourhassanExecutive officerDec 2021
Antonio G. Migliarese, C.P.A.Executive officerSep 2021
Christopher G. Recknor, M.D.Executive officerSep 2021
Nader Z. Pourhassan, Ph.D.Executive officerSep 2021
Nitya G. Ray, Ph.D.Executive officerSep 2021
Scott A Kelly, M.D.Executive officerSep 2021
Arian G. ColachisExecutive officerDec 2020
Mahboob G. Rahman, M.D., Ph.D.Executive officerDec 2020
Michael D. MulhollandExecutive officerDec 2020
Nader Z Pourhassan, Ph.DExecutive officerDec 2020
Scott Kelly, M.D.Executive officerDec 2020
Arian F ColachisExecutive officerApr 2020
Craig Z EastwoodExecutive officerApr 2020
Nader Z PourhassanExecutive officerApr 2020
Maura F FlemingExecutive officerFeb 2020
Richard G. PestellExecutive officerApr 2019
Anthony D. CaraccioloExecutive officerFeb 2018
Nadar Z. PourhassanExecutive officerNov 2017
Michael MulhollandExecutive officerOct 2013
Nadar PourhassanExecutive officerOct 2013
Nader PourhassanExecutive officerAug 2013
Richard TraugerExecutive officerFeb 2013
Andrew LibbyExecutive officerOct 2012
Andrew T. Libby, Jr.Executive officerJan 2012
Kenneth J. Van NessExecutive officerJan 2012
Karen J. Brunke, Ph.D.DirectorMay 2026
Lishomwa C. Ndhlovu, M.D., Ph.D.DirectorMay 2026
Ryan M. DunlapDirectorMay 2026
Stephen M. SimesDirectorMay 2026
Tanya D. UrbachDirectorMay 2026
Karen J. BrunkeDirectorSep 2022

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.